How Will Agilent Technologies (A) Stock Be Affected By Its Earnings Report?

NEW YORK (TheStreet) -- Agilent Technologies (A) reported a third quarter non GAAP net income of 78 cents per diluted share, 4 cents better than analysts were expecting.

Revenue for the quarter rose 7% to $1.77 billion ahead of analysts estimates of $1.75 billion.

However, the bio-analytical and electronic measurement company set fourth quarter earnings guidance between 87 cents and 91 cents per share, short of analysts expectations of 94 cents per share.

EXCLUSIVE OFFER: See inside Jim Cramer’s multi-million dollar charitable trust portfolio to see the stocks he and Stephanie Link think could be potentially HUGE winners. Click here to see the holdings for FREE.

Shares are up 0.7% to $56 in after-hours trading on Thursday.

TheStreet Ratings team rates AGILENT TECHNOLOGIES INC as a Buy with a ratings score of B. TheStreet Ratings Team has this to say about their recommendation:

"We rate AGILENT TECHNOLOGIES INC (A) a BUY. This is driven by several positive factors, which we believe should have a greater impact than any weaknesses, and should give investors a better performance opportunity than most stocks we cover. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, solid stock price performance, good cash flow from operations and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income."

Highlights from the analysis by TheStreet Ratings Team goes as follows:

A Chart A data by YCharts
EXCLUSIVE OFFER: See inside Jim Cramer’s multi-million dollar charitable trust portfolio to see the stocks he and Stephanie Link think could be potentially HUGE winners. Click here to see the holdings for FREE.

If you liked this article you might like

What a Difference a Day Makes for New SEC Rule

Jim Cramer: Agilent Technology Has Been One of My Favorites

Jim Cramer -- Agilent Is 'Continuing to Defy Gravity'

Biotech Movers: Disappointment for Bristol-Myers Kidney Combo Boosts Exelixis